Skip to content

Cervical Pessary to Prevent Preterm Singleton Birth in High Risk Population

Cervical Pessary to Prevent Preterm Singleton Birth in High Risk Population

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04147117
Enrollment
214
Registered
2019-10-31
Start date
2017-10-25
Completion date
2020-12-31
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Birth

Keywords

Preterm Birth, Cervical Pessary, Obstetrical history, Cervical length

Brief summary

DESIGN: Observational prospective study. INCLUSION CRITERIA: All women are 18 years old of age or older with high risk for preterm birth, based on clinical history, and between 18.0 weeks and 23.6 weeks of pregnancy. SAMPLE SIZE: 214 asymptomatic high risk pregnant women. METHODOLOGY: Patient selection, obtaining of informed consent, randomization for cervical placement of pessary. Current follow-up until delivery. Pessary is removed at 37 week or before in some specific situations. MAIN OUTCOME: sPTB \<370 weeks of gestation. SECONDARY OUTCOMES: Pregnancy outcomes and a neonatal composite morbidity. EXPECTED RESULTS: Cervical pessary reduces sPB below 37 weeks in high risk of preterm birth population.

Detailed description

Spontaneous preterm birth (sPB) is still a leading cause of neonatal and infant death and responsible of neonatal morbidity as cerebral palsy. In spite of improvements of neonatal care, rates of preterm birth have not changed in the recent 10 years. Clinical risk factors for preterm birth include: 1) Demographic characteristics such a low socioeconomic status, poor antenatal care, malnutrition or extremes in maternal age; 2) Behavioral factors including smoking, illicit drug abuse, alcohol consumption or heavy physical work; 3) Obstetric history including uterine malformation, previous preterm labor or preterm rupture of membranes (PROM), previous cervical surgery, late miscarriage \>16-17 weeks; 4) Aspects of the current pregnancy as multiple pregnancy, genital tract bleeding or infection, Preterm Rupture of Membranes (PROM), short cervix and others. In nulliparous women with no previous pregnancies or fetal losses \>16 weeks, screening based on clinical history (maternal racial origin, age, height, smoking status and method of conception) could detect about 20% of sPB. In women with previous pregnancies at or beyond 16 weeks the detection rate is doubled by incorporating obstetric history. The risks for women with a previous spontaneous preterm birth with a normal cervix in pregnancy are not negligible. It has been suggested that there is a continuum risk dependent on absolute cervical length while other authors showed that absolute length of cervix above 25mm had little impact on the risk of preterm birth before 35 weeks. A posterior study has not identified any clinical or obstetric risk factors in high-risk women with cervical length greater than 25mm that could help to identify those who will subsequently have a spontaneous preterm birth. The risk of preterm birth is inversely related to cervical length (CL) as measured by ultrasound. Current options for the management of short cervix in singleton pregnancies are: vaginal progesterone, with proved benefit; cervical cerclage in high risk and short cervix, and cervical pessary. Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall. Three randomized trials involving women with singleton low risk pregnancies and short cervix provided controversial results regarding the effect of cervical pessary on the rate of sPB before 34 weeks; in one trial, involving 380 women, the rate of this outcome was significantly lower with a pessary than with no pessary (6% vs 27%); in another trial, involving 108 women, there was no significant effect (9.4% vs 5.5%, respectively) and in the largest trial, involving 935 women, no benefits were found (12.9% vs 11.3%, respectively). Nowadays high-risk population with normal cervix is managed by cervical length surveillance and physical activity restriction, as progesterone has not a proved benefit in women at risk because of previous history but normal cervix. Cervical pessary has not been tested specifically in high risk population. In PECEP study a total number of 42 patients (11% of each group) had at least one previous preterm birth. Authors did not report differences in the risk of preterm birth before 34 weeks in this subgroup. In Nicolaides study, 154 patients had previous birth before 37 weeks: 70 were treated with pessary and 84 with expectant management. The reported risk of birth before 34 weeks was 10.1% and 19.5%, respectively. In spite of the increased risk in expectant group, these differences were not significant (OR 0.47 (0.18-1.21) p= 0.12). In both trials, women included has short cervix. Even that group of women with previous preterm birth were included in the previous trials, pessary has not been proved in a specific group of population with previous history of preterm birth or uterine-cervical factors. Therefore, there is a lack of information in this topic.

Interventions

Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.

Sponsors

Hospital Sant Joan de Deu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Singleton pregnancy. * Age \> 18 years old. * Gestational age between 18.0 -23.6 weeks of gestation. * Asymptomatic singleton pregnancies, with at least one of the following: * Previous spontaneous preterm delivery or PPROM (23 - 34.6 weeks). * Previous spontaneous second trimester miscarriage (16.0-22.6 weeks). * Previous surgery on uterine cervix. * Uterine malformation. * Able to sign informed consent form.

Exclusion criteria

* Congenital, chromosomal abnormalities or stillbirth in current pregnancy before randomization. * Women with an obstetrical history of iatrogenic preterm birth indicated for maternal or fetal conditions. * Symptomatic high-risk women or preterm prelabor rupture of membranes (PROM) in the current pregnancy. * Pregnant women with an indication of prophylactic cervical cerclage due to her own obstetrical history. * Pregnant women with an indication to perform a cervical cerclage, prior to study inclusion. * Cerclage in situ. * Active vaginal bleeding.

Design outcomes

Primary

MeasureTime frameDescription
Spontaneous preterm birth before 37 weeks of gestation3 yearsDelivery \< 37.0 weeks of gestation (Yes/No)

Secondary

MeasureTime frameDescription
Preterm birth 28 weeks5 monthsBirth before 28 weeks of gestation (Yes/No)
PPROM before 34 weeks5 monthsPreterm premature rupture of membranes before 34 weeks (Yes/No)
Threatened preterm labor5 monthsNumber of admissions for threatened preterm labor \<34weeks of gestation
Cervical trauma5 monthsSerious cervical or vaginal trauma (Yes/No)
Pessary tolerance5 monthsIntolerance to pessary (Yes/No)
Infection5 monthsVaginal infection (Yes/No)
Progesterone co-treatment5 monthsNeed for progesterone co-treatment (Yes/No)
Choriomanionitis5 monthsClinical chorioamnionitis (Yes/No)
Maternal mortality or morbidity5 monthsMaternal mortality or severe morbidity (Yes/No)
Preterm birth 34 weeks5 monthsBirth before 34 weeks of gestation (Yes/No)
Neonatal outcomes APGAR5 months5 min APGAR score \< 7 (Yes/No)
Neonatal outcomes umbilical artery pH5 monthsUmbilical artery pH at delivery \<7.1 (Yes/No)
Neonatal outcomes NICU5 monthsNeed for NICU admission (Yes/No)
Neonatal outcomes for respiratory support5 monthsNeed for respiratory support (Yes/No)
Neonatal outcomes SDR5 monthsRespiratory distress syndrome (Yes/No)
Neonatal outcomes IVH5 monthsIntraventricular haemorrhage (Yes/No)
Neonatal outcomes NEC5 monthsNecrotizing enterocolitis (Yes/No)
Neonatal outcomes. Death5 monthsNeonatal death (Yes/No)
Neonatal outcomes. Sepsis5 monthsNeonatal sepsis (Yes/No)
Neonatal birthweight5 monthsBirth weight in grams

Countries

Spain

Contacts

Primary ContactSilvia Irene Ferrero Martínez, MD,PhD
sferrero@sjdhospitalbarcelona.org+34932532100
Backup ContactNúria Lorente Colomé, MD
nlorente@sjdhospitalbarcelona.org+34932532100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026